General MedicationsINHALATIONStandard
FLOVENT HFA
FLUTICASONE PROPIONATE
Standard Dose
0.22MG/INH
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview FLOVENT HFA is listed in Drugs@FDA under application 021433 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient FLUTICASONE PROPIONATE Form and strength AEROSOL, METERED;INHALATION - 0.22MG/INH Sponsor GLAXO GRP LTD Submission history Latest submission status date: 2021-08-18 00:00:00.
Structured Monograph
Clinical summary
Approval overview FLOVENT HFA is listed in Drugs@FDA under application 021433 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient FLUTICASONE PROPIONATE Form and strength AEROSOL, METERED;INHALATION - 0.22MG/INH Sponsor GLAXO GRP LTD Submission history Latest submission status date: 2021-08-18 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.